ArticleCell cycle (Georgetown, Tex.)2014
Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.
Article in Cell cycle (Georgetown, Tex.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Significant association between Let-7-KRAS rs712 G > T polymorphism and cancer risk in the Chinese population: a meta-analysis.Oncotarget · 2017Pooled it
- Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer.Medical oncology (Northwood, London, England) · 2014Trial
- Interaction between microRNA and KRAS in Glioblastoma.Current medicinal chemistry · 2026Review
- Evaluation of genetic variation in tumor suppressor miRNA encoding and their target genes in breast cancer; focus on miRNA interaction and expression analysis.Frontiers in genome editing · 2026Article
- The microRNA Let-7 and its exosomal form: Epigenetic regulators of gynecological cancers.Cell biology and toxicology · 2024Review
- Review
- Association between KRAS gene polymorphisms and genetic susceptibility to breast cancer in a Chinese population.Journal of clinical laboratory analysis · 2023Article
- Interplay between K-RAS and miRNAs.Trends in cancer · 2022Review
- [Role and Significance of Bioactive Substances in Sputum in the Diagnosis of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Review
- Association of Rs61764370 polymorphism within let-7 microRNA-binding site with lung cancer in Iranian population.African health sciences · 2020Article
- The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas.The Journal of clinical investigation · 2020Article
- Association ofAging · 2019Article
- Long non-coding RNA NKILA inhibits proliferation and migration of lung cancer via IL-11/STAT3 signaling.International journal of clinical and experimental pathology · 2019Article
- Multidimensional communication of microRNAs and long non-coding RNAs in lung cancer.Journal of cancer research and clinical oncology · 2019Review
- miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.Molecular cancer · 2018Article
- Variant SNPs at the microRNA complementary site in the B7‑H1 3'‑untranslated region increase the risk of non‑small cell lung cancer.Molecular medicine reports · 2017Article
- KRAS and VEGF gene 3'-UTR single nucleotide polymorphisms predicted susceptibility in colorectal cancer.PloS one · 2017Article
- Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer.Oncotarget · 2016Article
- MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Association between theJournal of Cancer · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
While cancer is a serious health issue, there are very few genetic biomarkers that predict predisposition, prognosis, diagnosis, and treatment response. Recently, sequence variations that disrupt microRNA (miRNA)-mediated regulation of genes have been shown to be associated with many human diseases, including cancer. In an early example, a variant at one particular single nucleotide polymorphism (SNP) in a let-7 miRNA complementary site in the 3' untranslated region (3' UTR) of the KRAS gene was associated with risk and outcome of various cancers. The KRAS oncogene is an important regulator of cellular proliferation, and is frequently mutated in cancers. To discover additional sequence variants in the 3' UTR of KRAS with the potential as genetic biomarkers, we resequenced the complete region of the 3' UTR of KRAS in multiple non-small cell lung cancer and epithelial ovarian cancer cases either by Sanger sequencing or capture enrichment followed by high-throughput sequencing. Here we report a comprehensive list of sequence variations identified in cases, with some potentially dysregulating expression of KRAS by altering putative miRNA complementary sites. Notably, rs712, rs9266, and one novel variant may have a functional role in regulation of KRAS by disrupting complementary sites of various miRNAs, including let-7 and miR-181.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.